NICE guidance on radium–223 dichloride for hormone–relapsed prostate cancer with bone metastases

Umeweni, Nwamaka; Knight, Helen; McVeigh, Gary E.

doi:10.1016/s1470-2045(16)00060-7

Cited by 8 publications

(9 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with Umeweni et al (56), and according to NICE, the placebo plus best standard-of-care adopted in the ALSYMPCA trial cannot be considered the standard of care for mCRPCa since NICE had recommended abiraterone for patients in the post-docetaxel regimen.…”

Section: Association Sequence and Interactionssupporting

confidence: 56%

“…NICE guidance recommended 223 Ra post docetaxel-based treatment as second-line option and abiraterone for patients affected by mCRPCa previously treated with docetaxel (56). The only comparison between 223 Ra and abiraterone is an indirect one (57).…”

Section: % P<0001)mentioning

confidence: 99%

“…The NICE committee considered the cost-effectiveness of 223 Ra compared with abiraterone only for patients previous treated with docetaxel, assuming a pragmatic approach, in an uncertain economic model that did not consider the additional costs associated with the administration of a radiopharmaceutical (56). The Swedish National Board for Health and Welfare evaluated the cost per quality-adjusted life-year related to 223 Ra therapy, which was very high, and restricted its use to that following chemotherapy.…”

Section: Pharmacoeconomicsmentioning

confidence: 99%

See 2 more Smart Citations

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Buroni

Persico

Pasi

et al. 2016

View full text Add to dashboard Cite

Abstract. 223 Prostate cancer (PCa) is the most common malignancy in men (1). In patients affected by advanced PCa, defined as hormonesensitive disease since the tumor still requires androgen for growth, androgen deprivation therapy (ADT), including luteinizing hormone-releasing hormone (LHRH) agonists, antagonists and anti-androgens, represents the first-line treatment. Unfortunately some cancer cells develop resistance to ADT, indicating the progression of the disease to metastatic castration-resistant prostate cancer (mCRPCa). Such resistance to castration occurs in most patients (2) and, despite the approval of new therapeutic agents, mCRPCa remains a lethal disease (3). Nowadays the new therapeutic landscape for patients affected by mCRPCa aims to extend overall survival (OS) and includes cytotoxic, new-generation anti-androgens, immunotherapeutics and radiopharmaceuticals (4, 5).Bones are the preferred site of metastasis. Almost 90% of men who die from PCa have bone-metastatic disease (6), with a 5-year OS rate of 20%. Due to the fragility of bone with metastases, with the related risk of pain, fractures, spinal cord compression and hematological consequences, several drugs have been developed to treat the osseous involvement of this disease. In previous years, the optimal treatment aimed to relieve pain and reduce skeletal morbidity.Besides systemic therapies, bone-targeted agents that focus their activity on bone, such as bisphosphonates, monoclonal antibody and radiopharmaceuticals, have become available. The bisphosphonate zoledronic acid, the antibody to receptor activator of nuclear factor kappa-B ligand (RANKL) denosumab and radiopharmaceuticals [such as 89 Sr and 153 Sm-ethylene diamine tetramethylene phosphonate ( 153 Sm-EDTMP)], were approved for delaying skeletal-related events (SREs) and for the palliation of bone pain from mCRPCa. Radionuclide TherapyRadionuclide therapy is known to deliver ionizing radiation to tumor sites, thereby killing cancer cells (7). Bone-targeted radiopharmaceuticals localize their radiation to sites of high bone remodeling. 5719

show abstract

Section: Association Sequence and Interactionssupporting

confidence: 56%

Section: % P<0001)mentioning

confidence: 99%

Section: Pharmacoeconomicsmentioning

confidence: 99%

See 1 more Smart Citation

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Buroni

Persico

Pasi

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Their cost‐utility model revealed that docetaxel was associated with an incremental cost‐effectiveness ratio (ICER) of £32,706 ($51,028) per QALY gained compared with mitoxantrone. A more recent analysis of Medicare reimbursements for elderly men with metastatic prostate cancer indicated that those who received chemotherapy (either docetaxel or mitoxantrone) had an ICER of $99,146 per life‐year gained compared with those who did not receive chemotherapy (Table ) …”

Section: Prostate Cancermentioning

confidence: 99%

“…22 Table 2). 19,[23][24][25][26][27][28][29] The National Institute for Health and Care Excellence (NICE) examined the cost effectiveness of cabazitaxel compared with mitoxantrone. 27 On the basis of results from the TROPIC trial, 22 NICE investigators reported that cabazitaxel had an ICER of £82,950 ($109,153) per QALY gained compared with mitoxantrone.…”

Section: Effectiveness Of Docetaxel and Cabazitaxel For Crpcmentioning

confidence: 99%

Cost considerations for systemic therapy for patients with advanced genitourinary malignancies

Henry

Leung

Filson

2018

Cancer

View full text Add to dashboard Cite

The rising cost of health care in the United States has been the focus of intense debate within the medical, legal, and legislative arenas, with the cost of cancer care representing an important component. Cost effectiveness is not always easy to define, and there is no standard metric in assessing this measure related to cancer therapies. Significant controversy surrounds exactly what is the appropriate cost per added year of life. This review examines cost, effectiveness, and comparative cost effectiveness of novel systemic therapies for patients with urologic malignancies. Cancer 2018;124:2897-905. © 2018 American Cancer Society.

show abstract

Guidelines on Radioisotope Treatment of Bone Metastases in Prostate Cancer

Murphy

Evangelista

2018

Clinical Applications of Nuclear Medicine Targeted Therapy

View full text Add to dashboard Cite

NICE guidance on radium–223 dichloride for hormone–relapsed prostate cancer with bone metastases

Cited by 8 publications

References 3 publications

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Cost considerations for systemic therapy for patients with advanced genitourinary malignancies

Guidelines on Radioisotope Treatment of Bone Metastases in Prostate Cancer

Contact Info

Product

Resources

About